Q-omics provides the consensus-scored ELF3 profile across patient tissues and cancer cell-line models. ELF3 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, ELF3 is differentially expressed in 14, with the highest sampling consensus in KICH. Additionally, ELF3 RNA expression shows 16,116 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight OV, KICH, and KIRP as cancer lineages where ELF3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ELF3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ELF3 survival associations across molecular data types. ELF3 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ELF3 RNA expression–survival associations across cancer types. High ELF3 expression shows unfavorable associations in OV, ESCA, LGG and SKCM, but favorable associations in BLCA and HNSC. The OV Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify OV as the clearest survival context for ELF3 RNA expression.
This table summarizes ELF3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ELF3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ELF3 shows lower tumor expression in KICH, KIRC and HNSC and higher tumor expression in THCA, KIRP and UCEC. The KICH box plot shows higher ELF3 RNA expression in normal versus tumor tissue (log2 FC = −3.352, t-test p < 0.001).
This table shows molecular features associated with ELF3 in patient tissues and cancer cell lines. In patient samples, ELF3 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, ELF3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and LUNG_SCLC.
